Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only?
The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (L...
Main Authors: | Paulina Nazaruk, Marta Monticolo, Anna Maria Jędrzejczak, Natalia Krata, Barbara Moszczuk, Joanna Sańko-Resmer, Tomasz Pilecki, Arkadiusz Urbanowicz, Michał Florczak, Leszek Pączek, Bartosz Foroncewicz, Krzysztof Mucha |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/12/1454 |
Similar Items
-
Hybrid Immunity Provides the Best COVID-19 Humoral Response in Immunocompromised Patients with or without SARS-CoV-2 Infection History
by: Paulina Nazaruk, et al.
Published: (2023-08-01) -
Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
by: Palittiya Sintusek, et al.
Published: (2022-08-01) -
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
by: Marika Watanabe, et al.
Published: (2022-01-01) -
Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients—A Prospective Cohort Study
by: Yael Shostak, et al.
Published: (2023-04-01) -
High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
by: Yana Davidov, et al.
Published: (2022-12-01)